What is Biocardia Inc?
, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 11.88M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 54,200 shares $4k |
| 3-6months | 0 | 15146,500 shares $137k |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |